Substrate Specificity of Carboxylesterase Isozymes and Their Contribution to Hydrolase Activity in Human Liver and Small Intestine

Hydrolase activity from human liver and small intestine microsomes was compared with that of recombinant human carboxylesterases, hCE-1 and hCE-2. Although both hCE-1 and hCE-2 are present in human liver, the dominant component was found to be hCE-1, whereas the hydrolase activity of the human small...

Full description

Saved in:
Bibliographic Details
Published inDrug metabolism and disposition Vol. 34; no. 10; pp. 1734 - 1741
Main Authors Imai, Teruko, Taketani, Megumi, Shii, Mayumi, Hosokawa, Masakiyo, Chiba, Kan
Format Journal Article
LanguageEnglish
Published Bethesda, MD Elsevier Inc 01.10.2006
American Society for Pharmacology and Experimental Therapeutics
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Hydrolase activity from human liver and small intestine microsomes was compared with that of recombinant human carboxylesterases, hCE-1 and hCE-2. Although both hCE-1 and hCE-2 are present in human liver, the dominant component was found to be hCE-1, whereas the hydrolase activity of the human small intestine was found to be predominantly hCE-2. hCE-2 has a limited ability to hydrolyze large acyl compound substrates. Interestingly, propranolol derivatives, good substrates for hCE-2, were easily hydrolyzed by substitution of the methyl group on the 2-position of the acyl moiety, but were barely hydrolyzed when the methyl group was substituted on the 3-position. These findings suggest that hCE-2 does not easily form acylated intermediates because of conformational interference in its active site. In contrast, hCE-1 could hydrolyze a variety of substrates. The hydrolytic activity of hCE-2 increased with increasing alcohol chain length in benzoic acid derivative substrates, whereas hCE-1 preferentially catalyzed the hydrolysis of substrates with short alcohol chains. Kinetic data showed that the determining factor for the rate of hydrolysis of p-aminobenzoic acid esters was Vmax for hCE-1 and Km for hCE-2. Furthermore, the addition of hydrophobic alcohols to the reaction mixture with p-aminobenzoic acid propyl ester induced high and low levels of transesterification by hCE-1 and hCE-2, respectively. When considering the substrate specificities of hCE-1, it is necessary to consider the transesterification ability of hCE-1, in addition to the binding structure of the substrate in the active site of the enzyme.
AbstractList Hydrolase activity from human liver and small intestine microsomes was compared with that of recombinant human carboxylesterases, hCE-1 and hCE-2. Although both hCE-1 and hCE-2 are present in human liver, the dominant component was found to be hCE-1, whereas the hydrolase activity of the human small intestine was found to be predominantly hCE-2. hCE-2 has a limited ability to hydrolyze large acyl compound substrates. Interestingly, propranolol derivatives, good substrates for hCE-2, were easily hydrolyzed by substitution of the methyl group on the 2-position of the acyl moiety, but were barely hydrolyzed when the methyl group was substituted on the 3-position. These findings suggest that hCE-2 does not easily form acylated intermediates because of conformational interference in its active site. In contrast, hCE-1 could hydrolyze a variety of substrates. The hydrolytic activity of hCE-2 increased with increasing alcohol chain length in benzoic acid derivative substrates, whereas hCE-1 preferentially catalyzed the hydrolysis of substrates with short alcohol chains. Kinetic data showed that the determining factor for the rate of hydrolysis of p-aminobenzoic acid esters was V(max) for hCE-1 and K(m) for hCE-2. Furthermore, the addition of hydrophobic alcohols to the reaction mixture with p-aminobenzoic acid propyl ester induced high and low levels of transesterification by hCE-1 and hCE-2, respectively. When considering the substrate specificities of hCE-1, it is necessary to consider the transesterification ability of hCE-1, in addition to the binding structure of the substrate in the active site of the enzyme.
Hydrolase activity from human liver and small intestine microsomes was compared with that of recombinant human carboxylesterases, hCE-1 and hCE-2. Although both hCE-1 and hCE-2 are present in human liver, the dominant component was found to be hCE-1, whereas the hydrolase activity of the human small intestine was found to be predominantly hCE-2. hCE-2 has a limited ability to hydrolyze large acyl compound substrates. Interestingly, propranolol derivatives, good substrates for hCE-2, were easily hydrolyzed by substitution of the methyl group on the 2-position of the acyl moiety, but were barely hydrolyzed when the methyl group was substituted on the 3-position. These findings suggest that hCE-2 does not easily form acylated intermediates because of conformational interference in its active site. In contrast, hCE-1 could hydrolyze a variety of substrates. The hydrolytic activity of hCE-2 increased with increasing alcohol chain length in benzoic acid derivative substrates, whereas hCE-1 preferentially catalyzed the hydrolysis of substrates with short alcohol chains. Kinetic data showed that the determining factor for the rate of hydrolysis of p-aminobenzoic acid esters was Vmax for hCE-1 and Km for hCE-2. Furthermore, the addition of hydrophobic alcohols to the reaction mixture with p-aminobenzoic acid propyl ester induced high and low levels of transesterification by hCE-1 and hCE-2, respectively. When considering the substrate specificities of hCE-1, it is necessary to consider the transesterification ability of hCE-1, in addition to the binding structure of the substrate in the active site of the enzyme.
Hydrolase activity from human liver and small intestine microsomes was compared with that of recombinant human carboxylesterases, hCE-1 and hCE-2. Although both hCE-1 and hCE-2 are present in human liver, the dominant component was found to be hCE-1, whereas the hydrolase activity of the human small intestine was found to be predominantly hCE-2. hCE-2 has a limited ability to hydrolyze large acyl compound substrates. Interestingly, propranolol derivatives, good substrates for hCE-2, were easily hydrolyzed by substitution of the methyl group on the 2-position of the acyl moiety, but were barely hydrolyzed when the methyl group was substituted on the 3-position. These findings suggest that hCE-2 does not easily form acylated intermediates because of conformational interference in its active site. In contrast, hCE-1 could hydrolyze a variety of substrates. The hydrolytic activity of hCE-2 increased with increasing alcohol chain length in benzoic acid derivative substrates, whereas hCE-1 preferentially catalyzed the hydrolysis of substrates with short alcohol chains. Kinetic data showed that the determining factor for the rate of hydrolysis of p -aminobenzoic acid esters was V max for hCE-1 and K m for hCE-2. Furthermore, the addition of hydrophobic alcohols to the reaction mixture with p -aminobenzoic acid propyl ester induced high and low levels of transesterification by hCE-1 and hCE-2, respectively. When considering the substrate specificities of hCE-1, it is necessary to consider the transesterification ability of hCE-1, in addition to the binding structure of the substrate in the active site of the enzyme.
Author Hosokawa, Masakiyo
Chiba, Kan
Imai, Teruko
Taketani, Megumi
Shii, Mayumi
Author_xml – sequence: 1
  givenname: Teruko
  surname: Imai
  fullname: Imai, Teruko
  email: iteruko@gpo.kumamoto-u.ac.jp
– sequence: 2
  givenname: Megumi
  surname: Taketani
  fullname: Taketani, Megumi
– sequence: 3
  givenname: Mayumi
  surname: Shii
  fullname: Shii, Mayumi
– sequence: 4
  givenname: Masakiyo
  surname: Hosokawa
  fullname: Hosokawa, Masakiyo
– sequence: 5
  givenname: Kan
  surname: Chiba
  fullname: Chiba, Kan
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18154520$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/16837570$$D View this record in MEDLINE/PubMed
BookMark eNp1kEGP0zAQhS20iO0uXDkiX4BTih3HcXJcVUArVeLQReJmOc5ka5TYxXa6hCO_HGdTaU9cZsbS956f3g26ss4CQm8pWVOaF5_aoV1TUq4JqVlFX6AV5TnN0uvHFVqlRbKa8_Ia3YTwkxBaFKx-ha5pWTHBBVmhv4exCdGrCPhwAm06o02csOvwRvnG_Z56CBG8CoB3wf2ZBghY2RbfH8F4vHE2etOM0TiLo8PbqfWun-E7Hc15djIWb8dBWbw3Z_BP2sOg-h7vbEzWxsJr9LJTfYA3l32Lvn_5fL_ZZvtvX3ebu32mC1LETImO5DnNBROqY5QrkgZrOavrsiN1Tru8LkC0ggLJVVOLCqBqeC1qrRkHwm7Rh8X35N2vMf0tBxM09L2y4MYgy6oSJSdFAtcLqL0LwUMnT94Myk-SEjm3LlPr6S7l0noSvLs4j80A7TN-qTkB7y-AClr1nVdWm_DMVZQXPJ-5jwt3NA_HR-NBno7KD0q73j1MkhVPCQSbM1YLCamxswEvgzZgNbRJpaNsnflf2n-CAq39
CODEN DMDSAI
CitedBy_id crossref_primary_10_1016_j_snb_2024_135284
crossref_primary_10_1016_j_bcp_2008_12_017
crossref_primary_10_1016_j_ejphar_2017_11_036
crossref_primary_10_1002_pmic_202200176
crossref_primary_10_1016_j_bcp_2007_06_022
crossref_primary_10_1016_j_xphs_2017_12_004
crossref_primary_10_1016_j_ecoenv_2021_113124
crossref_primary_10_1016_j_xphs_2017_04_019
crossref_primary_10_1007_s40262_022_01129_y
crossref_primary_10_1016_j_bbrc_2017_03_014
crossref_primary_10_1007_s11356_016_7452_0
crossref_primary_10_1016_j_bcp_2021_114766
crossref_primary_10_1016_j_bcp_2021_114887
crossref_primary_10_1124_jpet_112_201640
crossref_primary_10_1016_j_bcp_2016_09_003
crossref_primary_10_1016_j_fct_2012_08_013
crossref_primary_10_1016_j_cbi_2019_108871
crossref_primary_10_1124_dmd_109_028209
crossref_primary_10_1007_s11095_014_1579_9
crossref_primary_10_1016_j_molmed_2018_06_001
crossref_primary_10_1124_dmd_108_024943
crossref_primary_10_1016_j_taap_2017_05_019
crossref_primary_10_1021_acs_jafc_9b03894
crossref_primary_10_3109_00498254_2010_526653
crossref_primary_10_1124_dmd_119_089011
crossref_primary_10_1016_j_dmpk_2022_100479
crossref_primary_10_1016_j_cbi_2021_109566
crossref_primary_10_1002_phar_1194
crossref_primary_10_1080_00498254_2019_1678078
crossref_primary_10_1124_dmd_120_000065
crossref_primary_10_1158_1078_0432_CCR_12_1184
crossref_primary_10_1016_j_bmcl_2018_02_035
crossref_primary_10_1016_j_rvsc_2019_07_013
crossref_primary_10_1016_j_ejpb_2012_11_008
crossref_primary_10_1124_dmd_107_015727
crossref_primary_10_1093_molbev_msn235
crossref_primary_10_1016_j_biopha_2023_114232
crossref_primary_10_1016_j_dmpk_2017_02_003
crossref_primary_10_1021_acs_molpharmaceut_6b00394
crossref_primary_10_1016_j_lfs_2021_119486
crossref_primary_10_1002_arch_21245
crossref_primary_10_1007_s00216_012_6576_4
crossref_primary_10_1038_ja_2014_91
crossref_primary_10_1038_srep44820
crossref_primary_10_1139_cjc_2015_0582
crossref_primary_10_1002_jps_23258
crossref_primary_10_1002_jps_24467
crossref_primary_10_1002_jps_21510
crossref_primary_10_1080_17425255_2018_1420164
crossref_primary_10_1111_bcpt_12625
crossref_primary_10_1016_j_bioorg_2019_103388
crossref_primary_10_1039_D0FO01732A
crossref_primary_10_1124_dmd_113_054049
crossref_primary_10_1124_dmd_107_016154
crossref_primary_10_1016_j_ejps_2017_09_040
crossref_primary_10_2133_dmpk_23_73
crossref_primary_10_5012_bkcs_2009_30_11_2631
crossref_primary_10_1016_j_bmcl_2011_12_005
crossref_primary_10_2217_pgs_2017_0052
crossref_primary_10_1186_s13287_023_03629_5
crossref_primary_10_1007_s10822_010_9373_1
crossref_primary_10_1080_00498254_2018_1435927
crossref_primary_10_3109_00498254_2013_802059
crossref_primary_10_1007_s11095_011_0637_9
crossref_primary_10_1124_dmd_119_089680
crossref_primary_10_1002_chir_23141
crossref_primary_10_1016_j_xphs_2023_01_025
crossref_primary_10_1097_MNM_0000000000000875
crossref_primary_10_1016_j_canlet_2016_04_041
crossref_primary_10_1016_j_toxlet_2014_10_026
crossref_primary_10_1038_tpj_2015_42
crossref_primary_10_1007_s13238_017_0437_z
crossref_primary_10_1016_j_ejps_2019_03_009
crossref_primary_10_1097_FPC_0b013e32830b0c5e
crossref_primary_10_1248_yakushi_127_611
crossref_primary_10_1016_j_fct_2019_110792
crossref_primary_10_1038_s41598_019_40487_9
crossref_primary_10_1074_jbc_M110_161802
crossref_primary_10_1124_dmd_112_044537
crossref_primary_10_1016_j_fct_2015_08_024
crossref_primary_10_1007_s11419_019_00491_0
crossref_primary_10_1128_AAC_02350_13
crossref_primary_10_1016_j_bcp_2024_116128
crossref_primary_10_1080_17512433_2022_2148655
crossref_primary_10_1021_acs_analchem_8b02101
crossref_primary_10_1080_03602532_2024_2368247
crossref_primary_10_1124_dmd_109_026567
crossref_primary_10_1186_s12885_024_12537_7
crossref_primary_10_2131_fts_5_185
crossref_primary_10_1007_s00228_012_1315_5
crossref_primary_10_3389_fnins_2019_00771
crossref_primary_10_1016_j_ejps_2019_105143
crossref_primary_10_1016_j_intimp_2014_12_003
crossref_primary_10_1124_dmd_121_000823
crossref_primary_10_2139_ssrn_2314621
crossref_primary_10_1016_j_bios_2016_04_075
crossref_primary_10_1186_s12859_018_2194_2
crossref_primary_10_1016_j_bmcl_2009_01_069
crossref_primary_10_1021_acs_jmedchem_0c00797
crossref_primary_10_1016_j_xphs_2020_10_018
crossref_primary_10_1016_j_cbi_2021_109744
crossref_primary_10_1124_dmd_124_001699
crossref_primary_10_1016_j_snb_2020_129312
crossref_primary_10_1124_dmd_113_051805
crossref_primary_10_1124_dmd_121_000513
crossref_primary_10_1016_j_xphs_2016_12_003
crossref_primary_10_1016_j_xphs_2016_12_001
crossref_primary_10_1016_j_ejmech_2020_112856
crossref_primary_10_1016_j_apsb_2018_05_005
crossref_primary_10_1021_acs_jmedchem_2c01039
crossref_primary_10_1016_j_bmcl_2017_02_037
crossref_primary_10_1124_dmd_111_041335
crossref_primary_10_1021_acs_jmedchem_7b01444
crossref_primary_10_1124_dmd_106_013862
crossref_primary_10_4062_biomolther_2009_17_4_335
crossref_primary_10_1016_j_cbi_2019_108914
crossref_primary_10_1007_s11745_010_3434_z
crossref_primary_10_3390_ijerph19127051
crossref_primary_10_1016_j_yrtph_2021_104918
crossref_primary_10_1124_dmd_118_086074
crossref_primary_10_1584_jpestics_R10_03
crossref_primary_10_1584_jpestics_R10_02
crossref_primary_10_1186_s13619_022_00118_7
crossref_primary_10_1002_bio_4392
crossref_primary_10_3390_molecules23020455
crossref_primary_10_1021_acs_jmedchem_0c02194
crossref_primary_10_1016_j_bbrc_2008_02_120
crossref_primary_10_1002_jps_24648
crossref_primary_10_1016_j_bcp_2016_12_010
crossref_primary_10_1080_00498254_2018_1474283
crossref_primary_10_1016_j_dmpk_2024_101005
crossref_primary_10_3390_pharmaceutics5030371
crossref_primary_10_1016_j_phytochem_2012_06_015
crossref_primary_10_1002_cpt_641
crossref_primary_10_1007_s11356_020_09427_3
crossref_primary_10_1097_FPC_0000000000000376
crossref_primary_10_1038_s41589_023_01301_w
crossref_primary_10_1248_bpb_b17_00880
crossref_primary_10_1038_s42003_024_06223_4
crossref_primary_10_1002_jps_24632
crossref_primary_10_1039_D1MD00073J
crossref_primary_10_1007_s00280_020_04087_z
crossref_primary_10_18632_oncotarget_6169
crossref_primary_10_3389_fchem_2014_00046
crossref_primary_10_1007_s00604_020_04296_6
crossref_primary_10_1016_j_fct_2013_12_013
crossref_primary_10_1080_00498254_2023_2298270
crossref_primary_10_1016_j_ijbiomac_2020_11_080
crossref_primary_10_1124_dmd_113_054551
crossref_primary_10_1007_s11172_019_2507_2
crossref_primary_10_1002_chem_201404675
crossref_primary_10_1124_dmd_113_051714
crossref_primary_10_3390_molecules13020412
crossref_primary_10_1371_journal_pone_0278111
crossref_primary_10_1016_j_dmpk_2023_100497
crossref_primary_10_1039_C5RA23614B
crossref_primary_10_3389_fphar_2017_00435
crossref_primary_10_1124_dmd_115_068221
crossref_primary_10_1016_j_bioorg_2023_106625
crossref_primary_10_1021_acs_jproteome_0c00787
crossref_primary_10_1124_dmd_113_056184
crossref_primary_10_3390_biom14020153
crossref_primary_10_1016_j_bcp_2018_01_028
crossref_primary_10_1016_j_ab_2017_10_014
crossref_primary_10_1208_s12248_009_9103_6
crossref_primary_10_1124_dmd_120_000283
crossref_primary_10_1124_dmd_108_020412
crossref_primary_10_1124_dmd_110_037937
crossref_primary_10_1097_JCP_0000000000001089
crossref_primary_10_1016_j_envint_2014_02_007
crossref_primary_10_1097_FPC_0b013e32834f03eb
crossref_primary_10_1007_s00216_020_02494_y
crossref_primary_10_1016_j_omtm_2021_05_005
crossref_primary_10_1002_chem_201504388
crossref_primary_10_1016_j_xphs_2023_03_018
crossref_primary_10_1021_acs_jproteome_3c00496
crossref_primary_10_1124_dmd_107_020248
crossref_primary_10_1111_acer_12364
crossref_primary_10_1016_j_xphs_2018_09_022
crossref_primary_10_1021_jacs_1c05908
crossref_primary_10_2133_dmpk_DMPK_12_RG_143
crossref_primary_10_1016_j_etap_2020_103561
crossref_primary_10_1039_C6DT01399F
crossref_primary_10_1124_dmd_111_039628
crossref_primary_10_1007_s11095_013_1158_5
crossref_primary_10_1016_j_comtox_2018_08_005
crossref_primary_10_1016_j_bioorg_2018_01_011
crossref_primary_10_2133_dmpk_21_173
crossref_primary_10_1007_s40262_014_0226_2
crossref_primary_10_1021_acs_jmedchem_5b00308
crossref_primary_10_1016_j_jconrel_2013_12_031
crossref_primary_10_1021_acs_jmedchem_7b01052
crossref_primary_10_1016_j_tiv_2017_06_020
crossref_primary_10_1517_17425255_2015_1042858
crossref_primary_10_1007_s00204_022_03332_z
crossref_primary_10_1093_toxsci_kfz149
crossref_primary_10_1016_j_fct_2013_03_036
crossref_primary_10_1016_j_ijpharm_2011_06_013
crossref_primary_10_1016_j_jpba_2019_02_004
crossref_primary_10_1016_j_stemcr_2018_10_019
crossref_primary_10_1016_j_eng_2021_09_014
crossref_primary_10_1016_j_cbi_2011_12_006
crossref_primary_10_1124_dmd_113_054353
crossref_primary_10_1016_j_lfs_2007_07_026
crossref_primary_10_1016_j_fitote_2017_01_010
crossref_primary_10_1517_17460441_2_7_923
crossref_primary_10_2174_1389200221666201217141025
crossref_primary_10_1016_j_ejps_2015_07_006
Cites_doi 10.1038/nsb790
10.1038/nsb0102-4
10.1248/bpb1978.4.879
10.1124/dmd.104.000554
10.1021/tx050072+
10.1016/S1074-5521(03)00071-1
10.1124/dmd.30.5.541
10.1016/S0006-8993(09)90022-1
10.1124/dmd.30.5.488
10.1038/nsb919
10.1016/0006-2952(80)90105-7
10.1111/j.2042-7158.1993.tb05547.x
10.1016/0006-2952(94)90461-8
10.1016/0003-9861(80)90386-0
10.1074/jbc.272.23.14769
10.1006/abbi.2001.2346
10.1248/bpb.20.869
10.1016/S0014-5793(99)01111-4
10.2174/1389200033489253
10.1016/S0003-9861(03)00286-8
10.1161/01.ATV.14.8.1346
10.1016/0003-2697(76)90527-3
10.1146/annurev.pharmtox.38.1.257
ContentType Journal Article
Copyright 2006 American Society for Pharmacology and Experimental Therapeutics
2006 INIST-CNRS
Copyright_xml – notice: 2006 American Society for Pharmacology and Experimental Therapeutics
– notice: 2006 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1124/dmd.106.009381
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1521-009X
EndPage 1741
ExternalDocumentID 10_1124_dmd_106_009381
16837570
18154520
34_10_1734
S0090955624036286
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.GJ
0R~
18M
2WC
4.4
53G
5GY
5RE
5VS
AAXUO
ABJNI
ABSQV
ACGFO
ACGFS
ACIWK
ACPRK
ADBBV
AENEX
AERNN
AFFNX
AFOSN
AFRAH
AI.
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
F9R
FDB
FRP
GX1
H13
HZ~
IH2
INIJC
KQ8
LSO
O9-
OK1
P2P
R0Z
RHF
RHI
RPT
SJN
TR2
VH1
W2D
W8F
WH7
WOQ
YCJ
YHG
ZGI
ZXP
~KM
-
08R
0R
AAPBV
AAWZA
ABFLS
ABSGY
ADACO
FH7
GJ
HZ
KM
O0-
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c404t-a7f02212737af315a03153d53996f0921f294e7d71e02ab978ee8b5979cc35e03
ISSN 0090-9556
IngestDate Sat Aug 17 00:51:00 EDT 2024
Fri Dec 06 04:38:34 EST 2024
Sat Sep 28 07:42:04 EDT 2024
Sun Oct 22 16:05:13 EDT 2023
Tue Jan 05 21:17:01 EST 2021
Sat Dec 14 16:13:47 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords Human
Digestive system
Enzyme
Isozyme
Liver
Substrate specificity
Hydrolases
Esterases
Carboxylesterase
Small intestine
Biological activity
Carboxylic ester hydrolases
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c404t-a7f02212737af315a03153d53996f0921f294e7d71e02ab978ee8b5979cc35e03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 16837570
PQID 68876504
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_68876504
crossref_primary_10_1124_dmd_106_009381
pubmed_primary_16837570
pascalfrancis_primary_18154520
highwire_pharmacology_34_10_1734
elsevier_sciencedirect_doi_10_1124_dmd_106_009381
ProviderPackageCode RHF
RHI
PublicationCentury 2000
PublicationDate 2006-10-01
PublicationDateYYYYMMDD 2006-10-01
PublicationDate_xml – month: 10
  year: 2006
  text: 2006-10-01
  day: 01
PublicationDecade 2000
PublicationPlace Bethesda, MD
PublicationPlace_xml – name: Bethesda, MD
– name: United States
PublicationTitle Drug metabolism and disposition
PublicationTitleAlternate Drug Metab Dispos
PublicationYear 2006
Publisher Elsevier Inc
American Society for Pharmacology and Experimental Therapeutics
Publisher_xml – sequence: 0
  name: Elsevier Inc
– name: American Society for Pharmacology and Experimental Therapeutics
References Beaumont, Webster, Gardner, Dack (bib1) 2003; 4
Xu, Zhang, Ma, McLeod (bib28) 2002; 8
Imai, Fukuhara, Ueda, Otagiri (bib18) 1993; 265
Pindel, Kedishvili, Abraham, Brzezinski, Zhang, Dean, Bosron (bib21) 1997; 272
Yamada, Hosokawa, Satoh, Moroo, Takahashi, Akatsu, Yamamoto (bib29) 1994; 658
Bencharit, Morton, Howard-Williams, Danks, Potter, Redinbo (bib3) 2002; 9
Takai, Matsuda, Usami, Adachi, Sugiyama, Katagiri, Tatematsu, Hirano (bib26) 1997; 20
Brzezinski, Abraham, Stone, Dean, Bosron (bib10) 1994; 48
Shameem, Imai, Otagiri (bib24) 1993; 45
Bencharit, Morton, Hyatt, Kuhn, Danks, Potter, Redinbo (bib4) 2003; 10
Furihata, Hosokawa, Nakata, Satoh, Chiba (bib13) 2003; 416
Bradford (bib8) 1976; 72
Yamaoka, Tanigawara, Nakagawa, Uno (bib30) 1981; 4
Zhang, Burnell, Dumaual, Bosron (bib31) 1999; 290
Huang, Fleming, Nishi, Redinbo, Hammock (bib16) 2005; 18
Mentlein, Heiland, Heymann (bib19) 1980; 200
Mori, Hosokawa, Ogasawara, Tsukada, Chiba (bib20) 1999; 458
Satoh, Hosokawa (bib22) 1998; 38
Bodor, Buchwald (bib6) 2002; 186
Becker, Bottcher, Lackner, Fehringer, Notka, Aslanidis, Schmitz (bib2) 1994; 14
Hosokawa, Endo, Fujisawa, Hara, Iwata, Sato, Satoh (bib14) 1995; 23
Bencharit, Morton, Xue, Potter, Redinbo (bib5) 2003; 10
Humerickhouse, Lohrbach, Li, Bosron, Dolan (bib17) 2000; 60
Xie, Yang, Liu, Xue, Yan (bib27) 2002; 30
Satoh, Taylor, Bosron, Sanghani, Hosokawa, Du (bib23) 2002; 30
Bosron, Hurley (bib7) 2002; 9
Brzezinski, Spink, Dean, Berkman, Cashman, Bosron (bib11) 1997; 25
Hosokawa, Suzuki, Takahashi, Mori, Satoh, Chiba (bib15) 2001; 389
Brandt, Heymann, Mentlein (bib9) 1980; 29
Buchwald, Bodor (bib12) 2002; 57
Tabata, Katoh, Tokudome, Nakajima, Yokoi (bib25) 2004; 32
2019091113262231000_34.10.1734.2
2019091113262231000_34.10.1734.1
(2019091113262231000_34.10.1734.28) 2002; 8
(2019091113262231000_34.10.1734.12) 2002; 57
(2019091113262231000_34.10.1734.17) 2000; 60
2019091113262231000_34.10.1734.27
(2019091113262231000_34.10.1734.18) 1993; 265
(2019091113262231000_34.10.1734.29) 1994; 658
(2019091113262231000_34.10.1734.11) 1997; 25
2019091113262231000_34.10.1734.9
2019091113262231000_34.10.1734.20
2019091113262231000_34.10.1734.8
(2019091113262231000_34.10.1734.14) 1995; 23
2019091113262231000_34.10.1734.21
2019091113262231000_34.10.1734.7
2019091113262231000_34.10.1734.22
2019091113262231000_34.10.1734.23
2019091113262231000_34.10.1734.5
2019091113262231000_34.10.1734.24
2019091113262231000_34.10.1734.4
2019091113262231000_34.10.1734.25
2019091113262231000_34.10.1734.3
2019091113262231000_34.10.1734.26
(2019091113262231000_34.10.1734.31) 1999; 290
2019091113262231000_34.10.1734.16
2019091113262231000_34.10.1734.19
2019091113262231000_34.10.1734.30
(2019091113262231000_34.10.1734.6) 2002; 186
2019091113262231000_34.10.1734.10
2019091113262231000_34.10.1734.13
2019091113262231000_34.10.1734.15
References_xml – volume: 9
  start-page: 4
  year: 2002
  end-page: 5
  ident: bib7
  article-title: Lessons from a bacterial cocaine esterase.
  publication-title: Nat Struct Biol
  contributor:
    fullname: Hurley
– volume: 32
  start-page: 1103
  year: 2004
  end-page: 1110
  ident: bib25
  article-title: Identification of the cytosolic carboxylesterase catalyzing the 5′-deoxy-5-fluorocytidine formation from capecitabine in human liver.
  publication-title: Drug Metab Dispos
  contributor:
    fullname: Yokoi
– volume: 20
  start-page: 869
  year: 1997
  end-page: 873
  ident: bib26
  article-title: Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver.
  publication-title: Biol Pharm Bull
  contributor:
    fullname: Hirano
– volume: 265
  start-page: 328
  year: 1993
  end-page: 333
  ident: bib18
  article-title: An evaluation of an anti-inflammatory-histamine H
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Otagiri
– volume: 10
  start-page: 341
  year: 2003
  end-page: 349
  ident: bib4
  article-title: Crystal structure of human carboxylesterase 1 complexed with the Alzheimer’s drug tacrine: from binding promiscuity to selective inhibition.
  publication-title: Chem-Biol
  contributor:
    fullname: Redinbo
– volume: 14
  start-page: 1346
  year: 1994
  end-page: 1355
  ident: bib2
  article-title: Purification, cloning, and expression of human enzyme with acyl coenzyme A:cholesterol acyl-transferase activity, which is identical to liver carboxylesterase.
  publication-title: Arterioscler Thromb
  contributor:
    fullname: Schmitz
– volume: 389
  start-page: 245
  year: 2001
  end-page: 253
  ident: bib15
  article-title: Purification, molecular cloning and expression of dog liver microsomal acyl-CoA hydrolase: a member of the carboxylesterase multigene family.
  publication-title: Arch Biochem Biophys
  contributor:
    fullname: Chiba
– volume: 72
  start-page: 248
  year: 1976
  end-page: 254
  ident: bib8
  article-title: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
  publication-title: Anal Biochem
  contributor:
    fullname: Bradford
– volume: 458
  start-page: 17
  year: 1999
  end-page: 22
  ident: bib20
  article-title: cDNA cloning, characterization and stable expression of novel human brain carboxylesterase.
  publication-title: FEBS Lett
  contributor:
    fullname: Chiba
– volume: 8
  start-page: 2605
  year: 2002
  end-page: 2611
  ident: bib28
  article-title: Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
  publication-title: Clin Cancer Res
  contributor:
    fullname: McLeod
– volume: 9
  start-page: 337
  year: 2002
  end-page: 342
  ident: bib3
  article-title: Structural insights into CPT-11 activation by mammalian carboxylesterases.
  publication-title: Nat Struct Biol
  contributor:
    fullname: Redinbo
– volume: 4
  start-page: 461
  year: 2003
  end-page: 485
  ident: bib1
  article-title: Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist.
  publication-title: Curr Drug Metab
  contributor:
    fullname: Dack
– volume: 25
  start-page: 1089
  year: 1997
  end-page: 1096
  ident: bib11
  article-title: Human liver carboxylesterase hCE-1: binding specificity for cocaine, heroin, and their metabolites and analogs.
  publication-title: Drug Metab Dispos
  contributor:
    fullname: Bosron
– volume: 38
  start-page: 257
  year: 1998
  end-page: 288
  ident: bib22
  article-title: The mammalian carboxylesterases: from molecules to functions.
  publication-title: Annu Rev Pharmacol Toxicol
  contributor:
    fullname: Hosokawa
– volume: 29
  start-page: 1927
  year: 1980
  end-page: 1931
  ident: bib9
  article-title: Selective inhibition of rat liver carboxylesterases by various organophosphorus diesters
  publication-title: Biochem Pharmacol
  contributor:
    fullname: Mentlein
– volume: 10
  start-page: 349
  year: 2003
  end-page: 356
  ident: bib5
  article-title: Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme.
  publication-title: Nat Struct Biol
  contributor:
    fullname: Redinbo
– volume: 186
  start-page: 301
  year: 2002
  end-page: 312
  ident: bib6
  article-title: Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites.
  publication-title: Methods Mol Biol
  contributor:
    fullname: Buchwald
– volume: 30
  start-page: 488
  year: 2002
  end-page: 493
  ident: bib23
  article-title: Current progress on esterases: from molecular structure to function.
  publication-title: Drug Metab Dispos
  contributor:
    fullname: Du
– volume: 18
  start-page: 1371
  year: 2005
  end-page: 1377
  ident: bib16
  article-title: Stereoselective hydrolysis of pyrethroid-like fluorescent substrates by human and other mammalian liver carboxylesterases.
  publication-title: Chem Res Toxicol
  contributor:
    fullname: Hammock
– volume: 60
  start-page: 1189
  year: 2000
  end-page: 1192
  ident: bib17
  article-title: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
  publication-title: Cancer Res
  contributor:
    fullname: Dolan
– volume: 416
  start-page: 101
  year: 2003
  end-page: 109
  ident: bib13
  article-title: Purification, molecular cloning, and functional expression of C57BL/6 inducible mouse liver acylcarnitine hydrolase, belonging to the carboxylesterase multigene family
  publication-title: Arch Biochem Biophys
  contributor:
    fullname: Chiba
– volume: 200
  start-page: 547
  year: 1980
  end-page: 559
  ident: bib19
  article-title: Simultaneous purification and comparative characterization of six serine hydrolases from rat liver microsomes.
  publication-title: Arch Biochem Biophys
  contributor:
    fullname: Heymann
– volume: 45
  start-page: 246
  year: 1993
  end-page: 252
  ident: bib24
  article-title: An in-vitro and in-vivo correlative approach to the evaluation of ester prodrugs to improve oral delivery of propranolol.
  publication-title: J Pharm Pharmacol
  contributor:
    fullname: Otagiri
– volume: 57
  start-page: 87
  year: 2002
  end-page: 93
  ident: bib12
  article-title: Physicochemical aspects of the enzymatic hydrolysis of carboxylic esters.
  publication-title: Pharmazie
  contributor:
    fullname: Bodor
– volume: 23
  start-page: 1022
  year: 1995
  end-page: 1027
  ident: bib14
  article-title: Interindividual variation in carboxylesterase levels in human liver microsomes.
  publication-title: Drug Metab Dispos
  contributor:
    fullname: Satoh
– volume: 290
  start-page: 314
  year: 1999
  end-page: 318
  ident: bib31
  article-title: Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1.
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Bosron
– volume: 4
  start-page: 879
  year: 1981
  end-page: 885
  ident: bib30
  article-title: A pharmacokinetic analysis program (MULTI) for microcomputer.
  publication-title: J Pharmacobio-Dyn
  contributor:
    fullname: Uno
– volume: 272
  start-page: 14769
  year: 1997
  end-page: 14775
  ident: bib21
  article-title: Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin.
  publication-title: J Biol Chem
  contributor:
    fullname: Bosron
– volume: 30
  start-page: 541
  year: 2002
  end-page: 547
  ident: bib27
  article-title: Human and rodent carboxylesterases: immunorelatedness, overlapping substrate specificity, differential sensitivity to serine enzyme inhibitors, and tumor-related expression.
  publication-title: Drug Metab Dispos
  contributor:
    fullname: Yan
– volume: 48
  start-page: 1747
  year: 1994
  end-page: 1755
  ident: bib10
  article-title: Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine.
  publication-title: Biochem Pharmacol
  contributor:
    fullname: Bosron
– volume: 658
  start-page: 163
  year: 1994
  end-page: 167
  ident: bib29
  article-title: Immunohistochemistry with an antibody to human liver carboxylesterase in human brain tissues.
  publication-title: Brain Res
  contributor:
    fullname: Yamamoto
– ident: 2019091113262231000_34.10.1734.3
  doi: 10.1038/nsb790
– ident: 2019091113262231000_34.10.1734.7
  doi: 10.1038/nsb0102-4
– ident: 2019091113262231000_34.10.1734.30
  doi: 10.1248/bpb1978.4.879
– ident: 2019091113262231000_34.10.1734.25
  doi: 10.1124/dmd.104.000554
– ident: 2019091113262231000_34.10.1734.16
  doi: 10.1021/tx050072+
– ident: 2019091113262231000_34.10.1734.4
  doi: 10.1016/S1074-5521(03)00071-1
– ident: 2019091113262231000_34.10.1734.27
  doi: 10.1124/dmd.30.5.541
– volume: 8
  start-page: 2605
  year: 2002
  ident: 2019091113262231000_34.10.1734.28
  publication-title: Clin Cancer Res
– volume: 60
  start-page: 1189
  year: 2000
  ident: 2019091113262231000_34.10.1734.17
  publication-title: Cancer Res
– volume: 658
  start-page: 163
  year: 1994
  ident: 2019091113262231000_34.10.1734.29
  publication-title: Brain Res
  doi: 10.1016/S0006-8993(09)90022-1
– volume: 186
  start-page: 301
  year: 2002
  ident: 2019091113262231000_34.10.1734.6
  publication-title: Methods Mol Biol
– ident: 2019091113262231000_34.10.1734.23
  doi: 10.1124/dmd.30.5.488
– ident: 2019091113262231000_34.10.1734.5
  doi: 10.1038/nsb919
– ident: 2019091113262231000_34.10.1734.9
  doi: 10.1016/0006-2952(80)90105-7
– ident: 2019091113262231000_34.10.1734.24
  doi: 10.1111/j.2042-7158.1993.tb05547.x
– ident: 2019091113262231000_34.10.1734.10
  doi: 10.1016/0006-2952(94)90461-8
– ident: 2019091113262231000_34.10.1734.19
  doi: 10.1016/0003-9861(80)90386-0
– ident: 2019091113262231000_34.10.1734.21
  doi: 10.1074/jbc.272.23.14769
– ident: 2019091113262231000_34.10.1734.15
  doi: 10.1006/abbi.2001.2346
– ident: 2019091113262231000_34.10.1734.26
  doi: 10.1248/bpb.20.869
– ident: 2019091113262231000_34.10.1734.20
  doi: 10.1016/S0014-5793(99)01111-4
– ident: 2019091113262231000_34.10.1734.1
  doi: 10.2174/1389200033489253
– ident: 2019091113262231000_34.10.1734.13
  doi: 10.1016/S0003-9861(03)00286-8
– ident: 2019091113262231000_34.10.1734.2
  doi: 10.1161/01.ATV.14.8.1346
– volume: 265
  start-page: 328
  year: 1993
  ident: 2019091113262231000_34.10.1734.18
  publication-title: J Pharmacol Exp Ther
– ident: 2019091113262231000_34.10.1734.8
  doi: 10.1016/0003-2697(76)90527-3
– ident: 2019091113262231000_34.10.1734.22
  doi: 10.1146/annurev.pharmtox.38.1.257
– volume: 25
  start-page: 1089
  year: 1997
  ident: 2019091113262231000_34.10.1734.11
  publication-title: Drug Metab Dispos
– volume: 57
  start-page: 87
  year: 2002
  ident: 2019091113262231000_34.10.1734.12
  publication-title: Pharmazie
– volume: 23
  start-page: 1022
  year: 1995
  ident: 2019091113262231000_34.10.1734.14
  publication-title: Drug Metab Dispos
– volume: 290
  start-page: 314
  year: 1999
  ident: 2019091113262231000_34.10.1734.31
  publication-title: J Pharmacol Exp Ther
SSID ssj0014439
Score 2.371805
Snippet Hydrolase activity from human liver and small intestine microsomes was compared with that of recombinant human carboxylesterases, hCE-1 and hCE-2. Although...
Hydrolase activity from human liver and small intestine microsomes was compared with that of recombinant human carboxylesterases, hCE-1 and hCE-2. Although...
SourceID proquest
crossref
pubmed
pascalfrancis
highwire
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 1734
SubjectTerms Animals
Benzoates - chemistry
Benzoates - metabolism
Biological and medical sciences
Carboxylesterase - genetics
Carboxylesterase - metabolism
Carboxylic Ester Hydrolases - genetics
Carboxylic Ester Hydrolases - metabolism
Cell Line
Flurbiprofen - chemistry
Flurbiprofen - metabolism
Humans
Hydrolases - metabolism
Hydrolysis
Intestine, Small - enzymology
Intestine, Small - metabolism
Isoenzymes - genetics
Isoenzymes - metabolism
Liver - enzymology
Liver - metabolism
Medical sciences
Microsomes - enzymology
Microsomes - metabolism
Microsomes, Liver - enzymology
Microsomes, Liver - metabolism
Molecular Structure
Pharmacology. Drug treatments
Propranolol - chemistry
Propranolol - metabolism
Substrate Specificity
Title Substrate Specificity of Carboxylesterase Isozymes and Their Contribution to Hydrolase Activity in Human Liver and Small Intestine
URI https://dx.doi.org/10.1124/dmd.106.009381
http://dmd.aspetjournals.org/content/34/10/1734.abstract
https://www.ncbi.nlm.nih.gov/pubmed/16837570
https://search.proquest.com/docview/68876504
Volume 34
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKcuGCeFMeiw9oOXSz5OEkzRHBoi4vgehKe4ucxFmqbpOqTQTZIz-bEzO2k7iFisclihw5cfvN2DPj8TeEPE0ckQuRB1bkscRijKcWtz1uOTBNch6AgStrRr7_EExO2Zsz_2ww-GFkLdVVcpRe_vZcyf-gCm2AK56S_Qdku5dCA9wDvnAFhOH6Vxij1kt2WVVGHskg2hNXq6T81lxIGgRYp0Yn6_KyQV4mjJNP5eYA8lK11a7QAp002Qr8XCQqSXVJCeTBkkH-d5i9obI8F7iXjXFEmBuKjTyiV6v6HCtSg1hdtKU3slmXFtbFCMSqnpejkwWfdWiL83oxG035HHoXfTNvsPnzl5nRtAaTtymx3kk551_5VtSizX-rjIMCOIMZuakfe7JuxT11bBY5mPbn0cwwph3ZVuT7mk5bT-KuY8GDM3OW1yFTLc22MWc7oXr262LiMpCAbJEdOXLLKvJUdRlDspYLKVpOAH6-ryqgbHJ6b621XQakx2J0v-DTV8hVJHHEug9vP_U7YIx5ynXTv08TjsKYnm-OCGlv9ed32VYd9TVm_vI1KH-uqrbsdqukeTW9Qa5rv4i-UEJ-kwxEcYscaKyaQ2rickgPqInibfK90wRqaAItc7qtCbTVBArQU6kJ1NQEWpW00wTaagKdFVRqApWaIPtKTaCdJtwhp6-Ppy8nlq4uYqXMZpXFwxzsVwfM95DnnuNzrHfiZcjUHOR25Dq5GzERZqEjbJcnUTgWYpyA_x2lqecL27tL9oqyEPcJTfIo8H3ugfMgGAvGCSyaKUvcSIQ-z1w-JM9aXOKlIpGR6AOYMYAJ95hbimAOidPCFmsTWJm2MQjlzj60xTdeGn9-3MvYkOxv4N6PYowulGsPyZNWEGJYX3DTkBeirNdxAFYIeHHwintKPvq-Wuoe_Pn7D8m1fhJ4RPaqVS0egzFfJftS6n8CBJ79Aw
link.rule.ids 314,780,784,27924,27925
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Substrate+Specificity+of+Carboxylesterase+Isozymes+and+Their+Contribution+to+Hydrolase+Activity+in+Human+Liver+and+Small+Intestine&rft.jtitle=Drug+metabolism+and+disposition&rft.au=Teruko+Imai&rft.au=Megumi+Taketani&rft.au=Mayumi+Shii&rft.au=Masakiyo+Hosokawa&rft.date=2006-10-01&rft.pub=American+Society+for+Pharmacology+and+Experimental+Therapeutics&rft.issn=0090-9556&rft.eissn=1521-009X&rft.volume=34&rft.issue=10&rft.spage=1734&rft_id=info:doi/10.1124%2Fdmd.106.009381&rft_id=info%3Apmid%2F16837570&rft.externalDBID=n%2Fa&rft.externalDocID=34_10_1734
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-9556&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-9556&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-9556&client=summon